Ascletis says FDA clears INDs for obesity candidates ASC36, ASC36_35FDC

• Ascletis received US FDA IND clearance to start two Phase 1 obesity studies of ASC36 and monthly fixed-dose combo ASC36_35FDC.
• Trials will assess safety, tolerability, pharmacokinetics, pharmacodynamics in obese or overweight adults; ASC36 targets amylin, combo adds GLP-1R/GIPR.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12278902), on August 10, 2026, and is solely responsible for the information contained therein.